AZD8330 First Time in Man in Patients With Advanced Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AZD5438 in Patients With Advanced Solid Malignancies

NCT00088790

Neoplasms

COMPLETED PHASE1

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

NCT01026402

Advanced Solid Malignancies

COMPLETED PHASE1

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

NCT00600496

Breast Cancer Breast Neoplasms Colon Cancer +5 more

ACTIVE_NOT_RECRUITING PHASE1

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

NCT00502060

Advanced Tumor

COMPLETED PHASE1

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

NCT00389389

Neoplasms

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD8330

oral tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ARRY-424704

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cancer which is refractory to standard therapies, or no therapies exist;

Exclusion Criteria

* Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;
* Hasn't participated in investigation drug study within 30 days;
* Brain metastases/spinal cord compression unless treated and stable,
* Off steroids/anticonvulsants.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No